Nextleaf launches a division of specialty molecules
News and research before you hear about it on CNBC et al. Claim your 1-week free trial for StreetInsider Premium here.
THC-O-acetate will be produced by the company’s Specialty Molecules division
Vancouver, British Columbia – (Newsfile Corp. – June 15, 2021) – Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf“,”OILS“, or the”Company“), an extraction company that holds one of the largest US patent portfolios for the extraction and distillation of cannabinoids, is pleased to announce the launch of a Specialty Molecules Division focus on the development and commercialization of new psychoactive compounds. The division is supported by the Company’s existing intellectual property (“IP”) portfolio, including the manufacture of CBD-O-acetate and the recently announced US patent for the synthesis of THC-O-acetate.
(Left to right: Dr Xuan Jia, Paul Pedersen, Ryan Ko, Dr David Novitski, Keenan Sindia)
To view an improved version of this graphic, please visit:
“The goal of this new division is to leverage Nextleaf’s existing intellectual property and delivery technology to develop intellectual property-protected therapeutics based on new molecules,” said Paul Pedersen, President and CEO General of OILS. “The business opportunity for our Specialty Molecules Division is to partner with larger organizations in the search for differentiation by leveraging the intellectual property of Nextleaf and Metro Vancouver’s licensed innovation lab and extraction plant to manufacture molecules specialty products licensed by Nextleaf from Health Canada. We anticipate our Specialty Molecules Division will play a major role in creating long-term value through the disruptive nature of our intellectual property, particularly with regard to the acetylation of cannabinoids, ”said Pedersen.
The cannabis industry has seen increased interest in new cannabinoid products with therapeutic and wellness applications, and investments from large pharmaceutical and CPG companies. British American Tobacco’s recent $ 221 million investment in Canadian cannabis producer Organigram is one example.
Nextleaf plans to announce a future R&D and innovation agreement with a major strategic partner operating in the field of cannabis or pharmacy.
The initial objective of the Specialty Molecules Division markets more complex cannabinoid-based treatments that could constitute a therapeutic alternative to opioid-based drugs. The Company currently holds the necessary pre-licenses under the Cannabis Act to market THC-O-acetate in Canada.
Nextleaf intends to develop therapeutic products based on its intellectual property relating to the acetylation of cannabinoids. The Company plans to launch products for adult use containing THC-O-acetate which, to the Company’s knowledge, have never been sold legally.
The Company believes that a THC derivative made with its patented acetylation process could have significant therapeutic potential due to anecdotal reports that THC-O-acetate has a more gradual onset, longer lasting effects, and effects. modified psychoactive agents, compared to Delta-9-THC. The reported improved potency may also have the potential to reduce the cost per dose and the amount of active ingredient in a formulation to achieve the same level of effect compared to Delta-9-THC.
Patents issued by Nextleaf in the United States and Canada describe a process for the acetylation of THC by refluxing naturally occurring THC distillate in the presence of a single reagent, THC-O-acetate being the product of the reaction. .
“This US patent covers our method of acetylating THC and follows on from our previous patent for the synthesis of THC-O-acetate, with improvements in reaction efficiency,” said patent author Dr. David Novitsky. “Our latest patented method reduces processing time and costs, which are critical when scaling up any drug delivery technology, and THC-O-acetate is no different.”
THC-O-acetate acts as a metabolic prodrug for THC, which can enhance absorption, metabolism, and distribution in the body. The prodrugs themselves are an inactive derivative that must be biologically transformed. in vivo to release the pharmacologically active parent drug, ideally a one-step enzymatic activation. Common examples of prodrugs include codeine, which is metabolized to morphine, a pain reliever, and psilocybin, which is metabolized to psilocin, a psychedelic form.
Nextleaf featured in Forbes
Nextleaf CEO Paul Pedersen was interviewed by Stephen Key, a Forbes contributor and leading expert on innovation, intellectual property and licensing. The interview focused on Nextleaf’s IP strategy and posted on the Forbes website last week. The article was the second such publication to feature Nextleaf, with a March 2021 Forbes article by Amanda Siebert focusing on the company’s groundbreaking human trials program.
Nextleaf is an innovative cannabis processor that has one of the largest US patent portfolios for the extraction, distillation and delivery of cannabinoids. Nextleaf supplies cannabis oils to its wholesale customers and distributes consumer products under its award-winning Prohibition-era brand, Glacial Gold. ”Nextleaf’s proprietary automated closed-loop extraction plant in the Greater Montreal area. Vancouver has a design capacity to turn 600 kilograms of dried cannabis into oil per day. Nextleaf is developing delivery technology through its research license from Health Canada with sensory evaluation of cannabis via human testing. The company has 14 US patents and has obtained 80 patents in the world.
Nextleaf Solutions trades under the names OILS on the Canadian Securities Exchange, OILFF on the OTCQB market in the United States and L0MA on the Frankfurt Stock Exchange.
Follow OILS on social media platforms: Twitter, LinkedIn, Facebook and Instagram.
For more information please contact:
Jason McBride, Business Development
604-283-2301 (ext. 219)
On behalf of the Board of Directors of the Company,
Paul Pedersen, CEO
Certain statements contained in this press release constitute “forward-looking statements”. All statements other than statements of historical fact contained in this press release, including, without limitation, those regarding the Company’s ability to capitalize on its intellectual property portfolio, the strategy, plans, objectives, goals and targets of the Company, as well as any statement preceded, followed or containing the words “believe”, “expect”, “aim”, “intend to” “,” Plan “,” continue “,” will “,” could “,” would “,” anticipate “,” estimate “,” foresee “,” predict “,” plan “,” seek “,” should “or similar or negative expressions thereof, are forward-looking statements. These statements are not historical facts but represent only the expectations, estimates and projections of the Company concerning future events. These statements are not guarantees of performance future and involve assumptions, risks and uncertainties that are difficult to predict. Therefore, actual results may differ materially from what is expressed, implied or expected in these forward-looking statements. Other factors that could cause results to differ materially. , actual performance or achievements include, but are not limited to, the risk factors described in the Company’s MD&A for the most recent year. Management provides forward-looking statements because they believe they provide information useful to investors when considering their investment objectives and cautions investors not to place undue reliance on forward-looking information. Accordingly, all forward-looking statements made in this press release are qualified by these and other cautions or factors contained herein, and there can be no assurance that actual results or developments will be achieved. or, even if they are substantially realized, that they will have the consequences or the expected effects on the Company. These forward-looking statements are made as of the date of this press release and the Company assumes no obligation to update or revise them to reflect subsequent information, events or circumstances or otherwise, except as required by law. required. The CSE has neither reviewed nor approved the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/87584